BOSNALIJEK / ABOUT US
Leading Pharmaceutical Company in Bosnia and Herzegovina
We are dedicated to the development of preventive action, palliation and cures and to improving the quality of life.
READ MORE
QUALITY, SAFETY AND EFFICACY
Continuously committed to the needs of our customers
We are committed to the continuous and consistent application of quality standards in all aspects of our business operations and processes.
READ MORE
CAREER / EDUCATION AND DEVELOPMENT
Our employees make our business successful
We devote special attention to talent management, career development and succession planning for key organisational positions.
READ MORE
BOSNALIJEK / SOS CHILDREN’S VILLAGES
We invest in our children’s healthy and carefree living
The second generation of children is being raised in an SOS children’s village family supported by Bosnalijek.
READ MORE
Products
We are continuously committed to our customers and pay special attention to monitoring and analysing their needs
MORE
Investors
We are committed to meeting the expectations of our customers, shareholders and employees
MORE
Products
We are continuously committed to our customers and pay special attention to monitoring and analysing their needs
MORE
Career
Join our family and make your contribution to improving the health of people around the world
MORE
We are building a safer future – Role of Enterofuryl in Eradication of Helicobacter pylori Bacterium
PRESS CENTRE / NEWS
We are building a safer future – Role of Enterofuryl in Eradication of Helicobacter pylori Bacterium
Prof. Dr. Leonid Lazebnik, President of Gastroenterological Scientific Society of Russia, held a speech on the topic “Role of Enterofuryl in Eradication of Helicobacter pylori”.
"We have positive experience with Enterofuryl in Russia and its effect has been confirmed. Therefore, our recommendation for the treatment of Helicobacter pylori is Enterofuryl, which is used across our country” said the esteemed Prof. Dr. Lazebnik.
MORE
SHAREHOLDERS/NOTICE
Notice of Reconvened Annual General Assembly of Bosnalijek d.d.
Annual General Assembly of Bosnalijek d.d. company is reconvened on 03/06/2017 with opening at 12:00 h. The Assembly session will be held…
In detail
PRES CENTER / MOSCOW
Excellent Sales Results on the Russian Market
he top generic maker of medicines in Bosnia and Herzegovina, Bosnalijek, continues to record growth on the Russian market, as stressed by the pharmaceutical...
In detail
FINANCIAL NEWS
Recapitalisation enabled New Investment in and the further Development of Bosnalijek
The sale of state owned capital and the successful recapitalisation of the company further strengthened the position of Bosnalijek and thus met the prerequisites for...
In detail
maj 25. 2017 |
SASE |
BSNLR - Bosnalijek d.d. Sarajevo: 12,47 3,89%